OR WAIT null SECS
The company has increased capacity for cold storage and controlled drug substances handling at its European facilities.
Catalent announced that it has expanded several capabilities within its European clinical supply services network to meet customer demand for specialty clinical packaging arising from the increasing proportion of highly potent and temperature-sensitive drugs.
The clinical storage capacity at Catalent's controlled substances facility in Deeside, UK, has been expanded with an additional third vault. This brings storage capacity to more than 14,000 cubic feet. The Deeside facility provides primary and secondary packaging services with cold storage capabilities for temperature-sensitive products and controlled drug substaces handling.
The Bathgate, UK facility's cold storage capabilities, on the other hand, now include a cryogenic storage service for stem cells, regenerative therapies, and other clinical materials. The company also installed two new energy efficient chiller units at its primary packaging facility in Bolton, UK, which is believed to increase output capacity by more than 10%.
Catalent has tripled its frozen storage capacity at its Schorndorf, Germany facility and added a second automated Inova packaging line for prefilled syringes, with capabilities such as plunger-rod insertion, application of single panel labels, finger flanges, and safety device mounting. This 60,000 square feet facility offers primary and secondary packaging for oral solid dossage forms and prefilled syringes; cold, frozen, and controlled drug clinical storage; and EU-GMP audit, importation, release and consulting services.
These four sites provide end-to-end clinical supply solutions that include clinical supply management and comparator sourcing.